To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes draft topic texts several weeks before the official Call launch. Indicative topics of Call 14 are now online.

Innovative Medicines Initiative - IMI

IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through Horizon 2020, IMI2 programme has a €3.3 billion budget for the period 2014-2020.

The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. IMI2 aims to facilitate the collaboration between the key players involved in healthcare research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

Call 14, indicative topics

Draft topic texts are subject to consultations involving IMI's States Representatives Group, Scientific Committee, and the European Commission. They must also be approved by the IMI Governing Board. Depending on the results of the consultations and approval process, the final topic text may differ significantly from the draft versions initially published here, and some topics may not be included in a Call in the end.

The following topics are currently under consideration for inclusion in future IMI Calls for proposals:

• Targeted immune intervention for treatment of non-response and remission
• Non-invasive clinical molecular imaging of immune cells
• Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
• Centre of excellence – remote decentralised clinical trials

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.

> Targeted immune intervention for treatment of non-response and remission

> Non-invasive clinical molecular imaging of immune cells

> Development of a platform for federated and privacy-preserving machine learning in support of drug discovery

> Centre of excellence – remote decentralised clinical trials

Photo on Foter.com